Low FODMAP Diet and Probiotics in Irritable Bowel Syndrome: A Systematic Review With Network Meta-analysis

Probiotic and low fermentable oligosaccharide, disaccharide, monosaccharide, and polyol (FODMAP) diet are two commonly used management approaches for patients with irritable bowel syndrome (IBS). We aimed to evaluate the most effective combinations and components among different probiotics or low FO...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in pharmacology Vol. 13; p. 853011
Main Authors Xie, Chao-Rong, Tang, Bin, Shi, Yun-Zhou, Peng, Wen-Yan, Ye, Kun, Tao, Qing-Feng, Yu, Shu-Guang, Zheng, Hui, Chen, Min
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 09.03.2022
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Probiotic and low fermentable oligosaccharide, disaccharide, monosaccharide, and polyol (FODMAP) diet are two commonly used management approaches for patients with irritable bowel syndrome (IBS). We aimed to evaluate the most effective combinations and components among different probiotics or low FODMAP diet through component network meta-analysis (NMA). We searched Embase, Ovid Medline, and Web of Science from inception to 21 January 2021. Randomized controlled trials (RCTs) examining the efficacy of probiotics and low FODMAP diet for IBS were included, with placebo, sham diet, or conventional treatments as controls. Binary outcomes were compared among treatments using the relative ratio (RR). A minimally contextualized framework recommended by the GRADE group was used to evaluate the certainty of evidence. The primary efficacy outcome was the relief of global IBS symptoms, and the secondary efficacy outcome was the reduction in IBS symptom scores or abdominal pain scores. We included 76 RCTs (n = 8058) after screening 1940 articles. Eight RCTs were classified as low risk of bias. Standard network meta-analysis (NMA) showed that (RR 1.74, 95% CI 1.22-2.48) and (RR 1.76, 95% CI 1.01-3.07) were the most effective for the primary efficacy outcome (high certainty evidence); component NMA showed that (RR 5.67, 95% CI 1.88 to 17.08, = 0.002) and (RR 1.42, 95% CI 1.07 to 1.91, = 0.017) were among the most effective components. The results of standard NMA and CNMA analysis of the improvement of overall IBS symptom scores or abdominal pain scores were consistent with this finding. was the most effective component for the relief of IBS symptoms; and were possibly effective and need further verification. website, identifier registration number.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
This article was submitted to Gastrointestinal and Hepatic Pharmacology, a section of the journal Frontiers in Pharmacology
Edited by: Raffaele Capasso, University of Naples Federico II, Italy
These authors have contributed equally to this work
Reviewed by: Chris Probert, University of Liverpool, United Kingdom
Isabelle Mack, University of Tübingen, Germany
ISSN:1663-9812
1663-9812
DOI:10.3389/fphar.2022.853011